174eP Progesterone receptor expression and endocrine therapy outcomes in low-grade serous ovarian carcinoma

ESMO Open · Published 2026-07-01 · DOI 10.1016/j.esmoop.2026.108221

Free full text

Authors (7)

B.A. Zengin, D.E. Yüksekli, M. Ugar, N. Ak, A. Toyran, S. Bagbudar, P.M. Saip

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Zengin, B., Yüksekli, D., Ugar, M., et al. (2026). 174eP Progesterone receptor expression and endocrine therapy outcomes in low-grade serous ovarian carcinoma. ESMO Open. https://doi.org/10.1016/j.esmoop.2026.108221

Related articles

• 61eP Radiotherapy combined with PARP inhibition in BRCA-mutated breast cancer: A systematic review of clinical outcomes and toxicity · ESMO Open · 2026 · Same journal
• Nectin-4 and Trop-2 expression in collecting duct carcinoma: new promising therapeutic targets · ESMO Open · 2026 · Same journal
• 149P Adjuvant radiotherapy outcomes for early stage (stage 1c-2) clear cell ovarian carcinoma in Edinburgh cancer centre · ESMO Open · 2026 · Same journal
• 213P Glandular tissue–based versus anatomical landmark–based CTV delineation in postoperative breast cancer radiotherapy: A dosimetric comparison · ESMO Open · 2026 · Same journal
• 194eP Ovarian cancer during pregnancy: Maternal and fetal outcomes from a systematic review and meta-analysis · ESMO Open · 2026 · Same journal
• 67RO Single-cell and TCR profiling reveals pre-existing cytotoxic CD8 T cell clonal expansion and peripheral–tumor dissociation associated with response to PD-1-based therapy in hepatocellular carcinoma · ESMO Open · 2026 · Same journal
• 219P Clinical profile and treatment outcomes of lymphoma patients: A retrospective cohort study · ESMO Open · 2026 · Same journal
• A phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the combination of atezolizumab with sacituzumab govitecan in patients with locally advanced or metastatic urothelial carcinoma and previously treated with a platinum-based treatment regimen (MORPHEUS-Urothelial Carcinoma) · ESMO Open · 2026 · Same journal
• 152P Efficacy and safety of relacorilant + nab-paclitaxel in patients aged ≥65 years with platinum-resistant ovarian cancer (PROC) in the phase III ROSELLA study (GOG-3073, ENGOT-ov72, APGOT-Ov10) · ESMO Open · 2026 · Same journal
• 232eP GLP-1 receptor agonists and risk of incident endometrial, colorectal, and hepatocellular cancer: A systematic review and meta-analysis · ESMO Open · 2026 · Same journal